Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes.
Michiko AsanoAkiko SekikawaHyosung KimRobert A GasserDarren RobertsonMarcella PetroneLutz JermutusPhilip AmberyPublished in: Diabetes, obesity & metabolism (2021)
Once-daily cotadutide was effective and well tolerated up to 300 μg in overweight Japanese patients with T2D. Further evaluation in Asian populations is warranted.